See more : AllianceBernstein Holding L.P. (AB) Income Statement Analysis – Financial Results
Complete financial analysis of Calyxt, Inc. (CLXT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Calyxt, Inc., a leading company in the Packaged Foods industry within the Consumer Defensive sector.
You may be interested
- Tethys Oil AB (publ) (0A1V.L) Income Statement Analysis – Financial Results
- Propanc Biopharma, Inc. (PPCB) Income Statement Analysis – Financial Results
- American International Industries, Inc. (AMIN) Income Statement Analysis – Financial Results
- Digital World Acquisition Corp. (DWACW) Income Statement Analysis – Financial Results
- Lloyds Banking Group plc 9.25% NON-CUM IRR PRF SHS GBP0.25 (LLOBF) Income Statement Analysis – Financial Results
Calyxt, Inc. (CLXT)
About Calyxt, Inc.
Calyxt, Inc., a synthetic biology company, engages in delivering plant-based solutions primarily to the agriculture end market in the United States. The company is involved in the development of improved digestibility alfalfa; hemp; and wheat with a higher fiber content. It has a commercialization agreement with S&W Seed Company for the exclusive license of an improved quality alfalfa seed in the United States and internationally. The company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. Calyxt, Inc. was incorporated in 2010 and is headquartered in Roseville, Minnesota. Calyxt, Inc. is a subsidiary of Cellectis S.A.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 157.00K | 25.99M | 23.85M | 7.30M | 236.00K | 508.00K | 399.00K | 1.27M |
| Cost of Revenue | 0.00 | 28.56M | 35.13M | 9.28M | 0.00 | 0.00 | 200.00K | 751.00K |
| Gross Profit | 157.00K | -2.57M | -11.28M | -1.98M | 236.00K | 508.00K | 199.00K | 521.00K |
| Gross Profit Ratio | 100.00% | -9.89% | -47.28% | -27.19% | 100.00% | 100.00% | 49.87% | 40.96% |
| Research & Development | 11.55M | 11.34M | 11.08M | 12.21M | 9.85M | 11.56M | 5.64M | 2.77M |
| General & Administrative | 0.00 | 0.00 | 16.16M | 18.97M | 18.51M | 14.74M | 6.67M | 3.57M |
| Selling & Marketing | 0.00 | 0.00 | 4.38M | 5.17M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.97M | 15.38M | 20.54M | 24.14M | 18.51M | 14.74M | 6.67M | 3.57M |
| Other Expenses | 5.57M | 45.00K | 252.00K | 1.34M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 22.53M | 26.76M | 31.87M | 37.69M | 28.35M | 26.30M | 12.31M | 6.34M |
| Cost & Expenses | 22.53M | 55.32M | 67.00M | 46.97M | 28.35M | 26.30M | 12.51M | 7.09M |
| Interest Income | 60.00K | 17.00K | 557.00K | 1.60M | 1.52M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 75.00K | 1.43M | 1.44M | 1.49M | 1.26M | 1.00K | 5.00K | 261.00K |
| Depreciation & Amortization | 1.53M | 810.00K | 3.24M | 3.21M | 1.08M | 551.00K | 345.00K | 147.00K |
| EBITDA | -22.37M | -28.52M | -40.59M | -36.47M | -28.12M | -25.79M | -11.74M | -5.48M |
| EBITDA Ratio | -14,248.41% | -109.75% | -170.19% | -499.81% | -10,830.08% | -5,005.51% | -2,941.35% | -430.90% |
| Operating Income | -22.37M | -29.33M | -43.83M | -39.67M | -28.12M | -25.79M | -12.11M | -5.81M |
| Operating Income Ratio | -14,248.41% | -112.87% | -183.77% | -543.76% | -11,913.14% | -5,076.57% | -3,034.84% | -457.08% |
| Total Other Income/Expenses | 5.48M | 133.00K | -1.00M | 61.00K | 218.00K | -191.00K | 23.00K | -75.00K |
| Income Before Tax | -16.89M | -29.20M | -44.84M | -39.61M | -27.90M | -25.98M | -12.09M | -5.89M |
| Income Before Tax Ratio | -10,758.60% | -112.36% | -187.98% | -542.93% | -11,820.76% | -5,114.17% | -3,029.07% | -462.97% |
| Income Tax Expense | -7.09M | -114.00K | 1.56M | 1.49M | 1.48M | -190.00K | 28.00K | 186.00K |
| Net Income | -9.80M | -29.09M | -46.40M | -41.10M | -27.90M | -25.98M | -12.09M | -5.89M |
| Net Income Ratio | -6,243.95% | -111.92% | -194.54% | -563.35% | -11,820.76% | -5,114.17% | -3,029.07% | -462.97% |
| EPS | -10.66 | -38.81 | -68.47 | -62.64 | -0.91 | -1.12 | -0.45 | -0.22 |
| EPS Diluted | -10.66 | -38.81 | -68.47 | -62.64 | -0.91 | -1.12 | -0.45 | -0.22 |
| Weighted Avg Shares Out | 919.95K | 749.52K | 677.65K | 656.11K | 30.68M | 23.15M | 26.60M | 26.60M |
| Weighted Avg Shares Out (Dil) | 919.95K | 749.52K | 677.65K | 656.11K | 30.68M | 23.15M | 26.60M | 26.60M |
Calyxt, Inc. (CLXT) CEO Michael Carr on Q1 2022 Results - Earnings Call Transcript
Calyxt, Inc. (NASDAQ:CLXT ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Bill Koschak - Chief Financial Officer Michael Carr - President and Chief Executive Officer Conference Call Participants Bobby Burleson - Canaccord Amit Dayal...
Calyxt to Host First Quarter 2022 Financial Results Conference Call and Webcast on Thursday, May 5, 2022, at 4:30 p.m. Eastern Time
ROSEVILLE, Minn. , April 21, 2022 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, will host a conference call and webcast on Thursday, May 5, 2022, at 4:30 p.m.
Calyxt Switches Gears Again, But The Cash Clock Keeps Ticking Down
Calyxt is now on to its third business plan, pivoting from gene-edited seed traits to synthetic biology. The company is looking to produce molecules of interest to pharmaceutical, nutraceutical, and cosmeceutical companies through sustainable plant-based technology.
Calyxt, Inc.'s (CLXT) CEO Michael Carr on Q4 2021 Results - Earnings Call Transcript
Calyxt, Inc.'s (CLXT) CEO Michael Carr on Q4 2021 Results - Earnings Call Transcript
Calyxt (CLXT) Reports Q4 Loss, Misses Revenue Estimates
Calyxt (CLXT) delivered earnings and revenue surprises of 17.39% and 42.28%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Calyxt to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call on Thursday, March 3, 2022, at 4:30 p.m. Eastern Time
ROSEVILLE, Minn., Feb. 24, 2022 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, will hold a conference call on Thursday, March 3, 2022, at 4:30 p.m.
7 of the Best Penny Stocks Under $3 for 2022 to Buy Now
Penny stocks under $3 are full of potential and potential pitfalls. These are relatively safe and worth your consideration.
Calyxt to Present at the 2021 Canaccord Genuity AgriFood Tech Innovation Virtual Forum
ROSEVILLE, Minn., Nov. 23, 2021 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biotechnology company, today announced that management will present at the 2021 Canaccord Genuity AgriFood Tech Innovation Virtual Forum.
Calyxt, Inc.'s (CLXT) CEO Michael Carr on Q3 2021 Results - Earnings Call Transcript
Calyxt, Inc.'s (CLXT) CEO Michael Carr on Q3 2021 Results - Earnings Call Transcript
5 Penny Stocks To Buy According To Analysts & Price Targets Up To 175%
Some of the best penny stocks 2021 has offered were some of… The post 5 Penny Stocks To Buy According To Analysts & Price Targets Up To 175% appeared first on Penny Stocks to Buy, Picks, News and Information |...
Source: https://incomestatements.info
Category: Stock Reports